NEW YORK (GenomeWeb News) – Response Genetics today reported that its second-quarter revenues nearly tripled, due to sales of the firm's ResponseDx genetic tests.

The Los Angeles-based firm reported total revenues of $5.6 million for the three-month period ended June 30, compared to $1.9 million for the second quarter of 2009. It said that sales of its ResponseDx tests increased 687 percent to $3.5 million for the quarter from $446,000 for Q2 2009.

Response Genetics also trimmed its net loss to $425,038, or $.02 per share, from $2.4 million, or $.19 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.